Tardive dyskinesia is a serious and disabling movement disorder that affects individuals treated with antipsychotic agents for a variety of mental health conditions. Though prevention and treatment primarily focus on stopping or changing the offending antipsychotic agent, for some individuals there are no other effective treatment options, and symptoms can persist after discontinuing or changing antipsychotic therapy.
Date of Review: December 2017
For questions or additional information, please contact firstname.lastname@example.org.
Interventions of Interest:
- Valbenazine (Ingrezza®, Neurocrine Biosciences, Inc)
- Deutetrabenazine (Austedo®, Teva)
- Tetrabenazine (Xenazine®)
View the Key Stakeholders List.
Below you will find the final documents from the assessment review process: